Innovative endpoint determination system for antifungal susceptibility testing of yeasts | Zendy

Raymond Tellier | Zendy; Mel Krajden | Zendy; G. A. Grigoriew | Zendy; Iain C. Campbell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Innovative endpoint determination system for antifungal susceptibility testing of yeasts

Author(s) -

Raymond Tellier,

Mel Krajden,

G. A. Grigoriew,

Iain C. Campbell

Publication year - 1992

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.36.8.1619

Subject(s) - fluconazole , antifungal , amphotericin b , microbiology and biotechnology , flucytosine , antifungal drugs , yeast , chemistry , pharmacology , biology , biochemistry

Fungal infections and antifungal resistance are increasingly recognized. Antifungal susceptibility testing remains unstandardized, and a particularly important problem is endpoint determination. In this paper we propose the yeast metabolic reduction of the tetrazolium salt 2,3-bis(2- methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetraz olium hydroxide (XTT) as a colorimetric endpoint which is quantitative and objective. Amphotericin B, fluorocytosine, and fluconazole dose-response curves were obtained, and a metabolic MIC could be determined by using precise criteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research